Modulators of antiestrogen pharmacology
OwnerMonica Montano, Amelia Suttoninventors
Life of this patent
Estimating the term…
Abstract
A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibiodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.
Claims8
An isolated polynucleotide comprising a nucleic acid sequence that encodes a protein comprising the amino acid sequence set forth in SEQ ID NO:
- 2, or the complete complement of said nucleic acid sequence, or both.
An isolated polynucleotide comprising a sequence which is complementary to the entire nucleic acid sequence set forth in SEQ ID NO:
- 1 or the protein encoding portion of SEQ ID NO:
- 1.
A primer set comprising a first purified primer comprising a sequence which is identical to a first sequence of 10 or more contiguous nucleotides in the protein encoding portion of SEQ ID NO.1, and a second purified primer comprising a sequence which is complementary to a second sequence of 10 or more contiguous nucleotides in the protein encoding sequence of SEQ ID NO. 1, wherein each of said primers has a G +C content of at least 40%.
A primer set comprising at least two purified oligonucleotides wherein one of said oligonucleotides comprises SEQ ID NO:
- 3 and another of said oligonucleotides comprises SEQ ID NO:4.
An isolated polynucteotide, comprising on or both of the following:
- (a) an altered SEQ ID NO. 1,
- (b) the complement of(a), wherein the alterations to SEQ ID NO:1 comprise one or both of the following:
- i) addition or inclusion of restriction sites in SEQ ID NO:
- 1;
- and
- ii) replacement of naturally occurring codons in SEQ ID NO:
- 1 with non-naturally occurring codons that permit expression of said polynucleotide in a host cell.
An isolated polynucleotide, comprising on or both of the following:
- (a) an altered protein encoding portion of SEQ ID NO. 1,
- (b) the complement of (a),
- wherein the alterations to the protein encoding portion of SEQ ID NO:1 comprise one or both of the following:
- i) addition or inclusion of restriction sites in the protein encoding portion of SEQ ID NO:
- 1;
- and ii) replacement of naturally occurring codons in the protein encoding portion of SEQ ID NO:
- 1 with non-naturally occurring codons that permit expression of said polynucleotide in a host cell.
Dependencies are inferred from the claim text.